

Brand Institute is proud to have partnered with 850 healthcare companies on over 3,100 names, including eighteen (18) COVID-19 products and product candidates to date!

Testing Apparatus/Diagnostic

ID NOW™
COVID-19

Rapid infectious disease detection and diagnosis



Abbott's molecular diagnostic platform that can test for the coronavirus (COVID-19) RdRp Gene and deliver positive results in as little as 5 minutes.

Antiviral Therapeutics

VEKLURY

Gilead's VEKLURY is an antiviral medication approved for post-infection treatment of COVID-19.

remdesivir

Gilead's Remdesivir is an antiviral medication approved for post-infection treatment of COVID-19.

galidesivir

BioCryst Pharmaceuticals' antiviral drug, Galidesivir, is being studied in Brazil as a potential treatment for COVID-19.

Compassionate Use Approvals

Yeliva®
 opaganib

RedHill Biopharma received approval for compassionate use of opaganib for COVID-19 in Italy and Israel.

Repurposed Drugs

CINVANTI®
 (aprepitant) injectable emulsion

Heron Therapeutics' CINVANTI is being studied as a potential treatment for COVID-19.

Bemcentinib

BerGenBio's Bemcentinib in being studied as a potential treatment for COVID-19 in hospitalized patients.

xofluza™
 (baloxavir marboxil) tablets 200mg

Roche & Shionogi's Xofluza (baloxavir marboxil) is being studied in combination with favipiravir and lopinavir-ritonavir as a potential treatment in novel coronavirus pneumonia (COVID-19) patients.

XPOVIO™
 (selinexor) 20 mg tablet

Karyopharm Therapeutics' XPOVIO is being studied as a potential treatment for hospitalized patients with COVID-19

KEVZARA®
 (sarilumab) injection
 200 mg | 150 mg

Sanofi's KEVZARA is being studied as a potential treatment for patients hospitalized with severe COVID-19 disease.

Brukinsa™
 zanubrutinib 80mg capsules

BeiGene's BRUKINSA is being studied in later-stage COVID-19 patients.

ULTOMIRIS®
 (ravulizumab-cwvz)
 injection for intravenous use
 300 mg/30 mL vial

Alexion's ULTOMIRIS is being studied as a potential treatment for adult COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS).

ACTEMRA®
 tocilizumab

Roche's ACTEMRA is being studied as a potential treatment for severely ill COVID-19 patients, who have been hospitalized with pneumonia.

JAKAVI®
 ruxolitinib

Novartis, in alliance with Incyte, has announced plans to assess Jakavi/Jakafi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe COVID-19 pneumonia.

CALQUENCE®
 (acalabrutinib) 100 mg capsules

AstraZeneca to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill COVID-19 patients.

ILARIS®
 (canakinumab)

Novartis has plans to conduct a Phase III clinical trial to assess Ilaris (canakinumab) for the treatment of patients suffering from COVID-19 pneumonia.

sylvant
 siltuximab

EUSA Pharma is studying Sylvant (siltuximab) as a treatment for patients with the COVID-19 coronavirus who have developed serious respiratory complications.

Colcrys™
 (colchicine, USP) tablets

Takeda Pharmaceuticals' Colcrys (colchicine) is being studied for potential efficacy against COVID-19 by Researchers at the Montreal Heart Institute and the University of Montreal.

Brand Institute is fully operational and ready to service your naming and branding needs. Please contact your local office if we can be of assistance.

Corporate Headquarters

200 SE 1st Street 12th Floor Miami, FL 33131 Telephone: (305) 374-2500 Fax: (305) 374-2504 www.brandinstitute.com

BASEL +41-78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49-1726-574-189	LONDON +44-7896-875-113	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364083	SEATTLE (206) 204-5111	SEOUL 82(0) 8000-4842	TOKYO 81(80) 6688-6653	TORONTO (416) 622-5777